ReviewCancers2016
A Second WNT for Old Drugs: Drug Repositioning against WNT-Dependent Cancers.
Review in Cancers, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Inhibition of WNT signaling sensitizes CRC cells to anti-tumor effects of retinoids: basis for new drug combinations in oncology.Cancer biology & therapy · 2026Article
- Cancer Therapy Using Antiparasitic Medications Guided by Acupuncture Meridian Assessment: A Case Series of Six Patients.Integrative medicine (Encinitas, Calif.) · 2026Article
- The role of KPNA3 in multiple myeloma: implications for targeting nuclear import.Apoptosis : an international journal on programmed cell death · 2026Article
- Review
- Challenging Reported Frizzled-Targeting Compounds in Selective Assays Reveals Lack of Functional Inhibition and Claimed Profiles.ACS pharmacology & translational science · 2024Article
- β-catenin inhibitors in cancer therapeutics: intricacies and way forward.Bioengineered · 2023Review
- Wnt-Independent SARS-CoV-2 Infection in Pulmonary Epithelial Cells.Microbiology spectrum · 2023Article
- Ethacrynic Acid: A Promising Candidate for Drug Repurposing as an Anticancer Agent.International journal of molecular sciences · 2023Review
- Wnt Signaling Inhibitors and Their Promising Role in Tumor Treatment.International journal of molecular sciences · 2023Review
- Synthesis and Cytotoxic Activity of 1,2,4-Triazolo-LinkedMolecules (Basel, Switzerland) · 2022Article
- Article
- Bortezomib potentiates antitumor activity of mitoxantrone through dampening Wnt/β-catenin signal pathway in prostate cancer cells.BMC cancer · 2021Article
- Suramin attenuates intervertebral disc degeneration by inhibiting NF-κB signalling pathway.Bone & joint research · 2021Article
- Repositioning of antidepressant drugs and synergistic effect with ciprofloxacin against multidrug-resistant bacteria.World journal of microbiology & biotechnology · 2021Article
- Effects of salinomycin and niclosamide on small cell lung cancer and small cell lung cancer circulating tumor cell lines.Investigational new drugs · 2020Article
- Drug repositioning in cancer: The current situation in Japan.Cancer science · 2020Review
- Small Molecule Wnt Pathway Modulators from Natural Sources: History, State of the Art and Perspectives.Cells · 2020Review
- Unbiased Phenotype-Based Screen Identifies Therapeutic Agents Selective for Metastatic Prostate Cancer.Frontiers in oncology · 2020Article
- Beyond TNBC: Repositioning of Clofazimine Against a Broad Range of Wnt-Dependent Cancers.Frontiers in oncology · 2020Article
- Extracellular ATP Mediates Cancer Cell Migration and Invasion Through Increased Expression of Cyclooxygenase 2.Frontiers in pharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aberrant WNT signaling underlies cancerous transformation and growth in many tissues, such as the colon, breast, liver, and others. Downregulation of the WNT pathway is a desired mode of development of targeted therapies against these cancers. Despite the urgent need, no WNT signaling-directed drugs currently exist, and only very few candidates have reached early phase clinical trials. Among different strategies to develop WNT-targeting anti-cancer therapies, repositioning of existing drugs previously approved for other diseases is a promising approach. Nonsteroidal anti-inflammatory drugs like aspirin, the anti-leprotic clofazimine, and the anti-trypanosomal suramin are among examples of drugs having recently revealed WNT-targeting activities. In total, 16 human-use drug compounds have been found to be working through the WNT pathway and show promise for their prospective repositioning against various cancers. Advances, hurdles, and prospects of developing these molecules as potential drugs against WNT-dependent cancers, as well as approaches for discovering new ones for repositioning, are the foci of the current review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.